Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Clinical trial NCT03456726 · COMPLETED
Trial details
- NCT number
- NCT03456726
- Sponsor
- Eisai Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-09
- Primary completion
- 2021-12-17
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.